Drugs / Naptumomab estafenatox
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05894447 | Nov 2023 → Dec 2025 | urothelial carcinoma | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 1 | NCT03983954 | Oct 2019 → Mar 2027 expected | cervical squamous cell carcinoma, colorectal cancer, endometrial cancer, esophageal cancer +14 | NeoTX Therapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00132379 | Nov 2005 → Dec 2006 | non-small cell lung carcinoma | Active Biotech AB | Completed | No outcome recorded |
| Phase 1 | NCT00056537 | Apr 2003 → Dec 2006 | clear cell renal carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma | Active Biotech AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04880863 | Oct 2021 → Jan 2024 | non-small cell lung carcinoma | NeoTX Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00420888 | Jan 2007 → Jan 2013 | renal cell carcinoma | Active Biotech AB | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naptumomab estafenatox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03983954 ↗ |
| Known as | ABR-217620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00420888 ↗ |
| Known as | ANYARA | “Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies.” PMID 25669986 ↗ Feb 2015 |
| Known as | ANYARA TTS CD3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743045 ↗ |
| Known as | NAP | “Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional...” NCT04880863 ↗2“Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With...” NCT03983954 ↗ “A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial Cancers” NCT05894447 ↗ |
| Known as | TTS-CD3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743045 ↗ |
| Action | Activate | “triggers an attack on the tumor cells by activating some white blood cells” NCT00132379 ↗ |
| Modality | Protein / enzyme biologic | “ABR-217620 is a combination of two proteins” NCT00056537 ↗ |
| Route | Intravenous | “10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection” NCT00132379 ↗ |
| Target | TPBG | “Trophoblast glycoprotein other” CHEMBL1743045 ↗ |